• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Intermittent treatment of metastatic malignant melanoma with high-dose 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388).

作者信息

Cowan D H, Bergsagel D E

出版信息

Cancer Chemother Rep. 1971 Apr;55(2):175-81.

PMID:5118686
Abstract
摘要

相似文献

1
Intermittent treatment of metastatic malignant melanoma with high-dose 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388).用高剂量5-(3,3-二甲基-1-三氮烯基)咪唑-4-甲酰胺（NSC-45388）间歇性治疗转移性恶性黑色素瘤。
Cancer Chemother Rep. 1971 Apr;55(2):175-81.
2
Clinical trials of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) given intravenously in the treatment of malignant melanoma in Uganda.5-（3,3-二甲基-1-三氮烯基）咪唑-4-甲酰胺（NSC-45388）静脉给药治疗乌干达恶性黑色素瘤的临床试验。
Cancer Chemother Rep. 1971 Apr;55(2):143-9.
3
Study of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in patients with disseminated melanoma.5-（3,3-二甲基-1-三氮烯基）咪唑-4-甲酰胺（NSC-45388）治疗播散性黑色素瘤患者的研究。
Cancer Chemother Rep. 1973 Feb;57(1):83-4.
4
Treatment of metastatic malignant melanoma with a combination of 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388), cyclophosphamide (NSC-26271), and vincristine (NSC-67574).采用5-（3,3-二甲基-1-三氮烯基）咪唑-4-甲酰胺（NSC-45388）、环磷酰胺（NSC-26271）和长春新碱（NSC-67574）联合治疗转移性恶性黑色素瘤。
Cancer Chemother Rep. 1972 Jun;56(3):357-61.
5
A comparative study of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037) and imidazole carboxamide (NSC 45388) with vincristine (NSC 67574) in the palliation of disseminated malignant melanoma.1-(2-氯乙基)-3-环己基-1-亚硝基脲（NSC 79037）、咪唑甲酰胺（NSC 45388）与长春新碱（NSC 67574）用于缓解播散性恶性黑色素瘤的对比研究
Cancer Res. 1972 Nov;32(11):2432-4.
6
Intra-arterial infusion therapy with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC 45388) for malignant melanoma.采用5-（3,3-二甲基-1-三氮烯基）咪唑-4-甲酰胺（NSC 45388）进行动脉内灌注治疗恶性黑色素瘤。
Cancer. 1973 Oct;32(4):749-55. doi: 10.1002/1097-0142(197310)32:4<749::aid-cncr2820320403>3.0.co;2-1.
7
Clinical experience with 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) in the treatment of metastatic malignant melanoma.5-（3,3-双（2-氯乙基）-1-三氮烯基）咪唑-4-甲酰胺（NSC-82196）治疗转移性恶性黑色素瘤的临床经验
Cancer Chemother Rep. 1972 Oct;56(5):671-7.
8
Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin.用二甲基三氮烯咪唑甲酰胺和卡介苗对播散性恶性黑色素瘤进行化学免疫治疗。
N Engl J Med. 1974 Sep 19;291(12):592-7. doi: 10.1056/NEJM197409192911202.
9
Preliminary clinical trial and the physiologic disposition of 4(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide in man.4(5)-(3,3-二甲基-1-三氮烯基)咪唑-5(4)-甲酰胺在人体中的初步临床试验及生理处置
Cancer Res. 1969 Nov;29(11):1944-51.
10
Central nervous system complications after combination treatment with adriamycin (NSC-123127) and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388).阿霉素（NSC - 123127）与5 -（3,3 - 二甲基 - 1 - 三氮烯基）咪唑 - 4 - 甲酰胺（NSC - 45388）联合治疗后的中枢神经系统并发症
Cancer Chemother Rep. 1974 Sep-Oct;58(5 Pt 1):753-4.

引用本文的文献

1
WITHDRAWN: Systemic treatments for metastatic cutaneous melanoma.撤回：转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 7;2(2):CD001215. doi: 10.1002/14651858.CD001215.pub2.
2
Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.在晚期恶性黑色素瘤中序贯给予不同剂量的达卡巴嗪和福莫司汀。
Br J Cancer. 1993 Jun;67(6):1356-60. doi: 10.1038/bjc.1993.251.
3
Mechanisms of hepatotoxicity caused by dacarbazine in rats.达卡巴嗪对大鼠肝毒性的作用机制
J Cancer Res Clin Oncol. 1993;119(8):475-81. doi: 10.1007/BF01215928.
4
Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion.CB10 - 277通过24小时持续输注给药的I期药代动力学试验。
Br J Cancer. 1993 Feb;67(2):369-73. doi: 10.1038/bjc.1993.67.
5
Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells.达卡巴嗪（DTIC）和福莫司汀对人外周血单个核细胞中O6-烷基鸟嘌呤-DNA烷基转移酶的剂量及周期效应
Br J Cancer. 1993 Feb;67(2):216-21. doi: 10.1038/bjc.1993.42.
6
A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors.达卡巴嗪联合自体骨髓移植治疗实体瘤患者的I期临床及药理学研究
Invest New Drugs. 1993 May-Aug;11(2-3):169-79. doi: 10.1007/BF00874151.
7
Cranial computed tomography of patients with malignant melanoma.恶性黑色素瘤患者的头颅计算机断层扫描
Neuroradiology. 1981;22(3):123-7. doi: 10.1007/BF00346752.
8
Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules.达卡巴嗪（DTIC）及其代谢产物5-氨基咪唑-4-甲酰胺（AIC）在不同给药方案后的药代动力学。
Cancer Chemother Pharmacol. 1982;9(2):103-9. doi: 10.1007/BF00265388.
9
Clinical pharmacokinetics of high-dose DTIC.大剂量达卡巴嗪的临床药代动力学
Cancer Chemother Pharmacol. 1991;28(6):475-9. doi: 10.1007/BF00685826.
10
Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.复发性恶性黑色素瘤：辅助免疫治疗对生存的影响。
Can Med Assoc J. 1977 Jul 9;117(1):33-6.